inmunebio.jpg
INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRPα
October 30, 2023 09:07 ET | INmune Bio, Inc.
SIRP-CD47 is an innate immune checkpoint known as the “don’t eat me” signal. INB03 downregulates expression of SIRPα on macrophages promote increased cancer cell death by antibody dependent cellular...
purple-logo2020.png
Purple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of Action
October 06, 2023 07:50 ET | Purple Biotech Ltd.
REHOVOT, Israel, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that...
purple-logo2020.png
Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer
October 03, 2023 07:50 ET | Purple Biotech Ltd.
Anti-tumor activity noted in the highest dose cohort of NT219 in combination with cetuximab;  2 out of 4 SCCHN patients at the highest dose cohort demonstrated a confirmed partial responseNT219...
scilogo.jpg
SciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder
September 29, 2023 07:45 ET | SciSparc Ltd
TEL AVIV, Israel, Sept. 29, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
LOGO roboto color with gray.png
Folia Health launches user-led research program, the Canopy Series
May 23, 2023 10:09 ET | Folia Health
BOSTON, May 23, 2023 (GLOBE NEWSWIRE) -- Today, Folia Health announced a first-of-its-kind observational research initiative driven by the priorities of patient and caregiver users. This program,...
sensus_logo.jpg
Sensus Healthcare's SRT Treatment Shows Promise in Treating Cutaneous Mast Cell Tumors Among Pet Patients
May 17, 2023 08:00 ET | Sensus Healthcare, Inc.
BOCA RATON, Fla, May 17, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare Inc. (Nasdaq:SRTS), the leading manufacturer of advanced medical devices for non-surgical skin cancer and keloid scar treatment,...
scilogo.jpg
SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer's Disease and Agitation
May 02, 2023 07:25 ET | SciSparc Ltd
The Company previously announced positive interim results from the trial meeting its primary endpoints TEL AVIV, Israel, May 02, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or...
Coya Therapeutics White Background.jpg
Coya Therapeutics, Inc. Announces Peer-Reviewed Publication of Phase 2a Clinical Trial Data for COYA 101 in Amyotrophic Lateral Sclerosis (ALS)
September 01, 2022 09:27 ET | Coya Therapeutics, Inc.
Phase 2a publication entitled “Combined Regulatory T-Lymphocyte and IL-2 Treatment is Safe, Tolerable, and Biologically Active for One Year in Persons with Amyotrophic Lateral Sclerosis” has been...
HTI Logo Color Vertical Jpeg.jpg
Healthcare Triangle Facilitates Secure Data Sharing for Drug Discovery Through Neutral Zone
July 05, 2022 08:00 ET | Healthcare Triangle, Inc.
PLEASANTON, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Healthcare Triangle Inc., (Nasdaq: HCTI) (“HCTI” or the "Company") enables collaborative data sharing and analysis through “neutral zone”. A...
Coya Therapeutics White Background.jpg
Coya Therapeutics Announces Peer-Reviewed Publication of its First-in-Class Regulatory T Cell-derived Exosomes and their Therapeutic Potential in Neurodegeneration and Inflammation Related Diseases
June 23, 2022 09:27 ET | Coya Therapeutics, Inc.
Regulatory T Cell (Treg)-derived exosome data have been published in the peer-reviewed journal Frontiers of Immunology Characterization of Treg-derived exosomes show Treg cells-conserved functional...